腹膜透析相关腹膜纤维化的防治进展  

Progress of research on prevention and treatment of peritoneal dialysis-related peritoneal fibrosis

作　　者：邹庚艺 曹雪莹[1] 周建辉[1] 陈香美[1] 

机构地区：[1]解放军总医院肾脏病科、解放军肾脏病研究所、肾脏疾病国家重点实验室、国家慢性肾病临床医学研究中心,北京100853 [2]南开大学医学院,天津300071

出　　处：《中华肾病研究电子杂志》2016年第1期42-44,共3页Chinese Journal of Kidney Disease Investigation（Electronic Edition）

基　　金：中华医学会临床医学科研专项基金-施维雅肾脏病青年研究与发展项目(15020050593)

摘　　要：腹膜纤维化(PF)是终末期肾病(ESRD)患者退出腹膜透析的主要原因。腹膜组织长期暴露于腹膜透析液中,致腹膜形态及功能发生改变,并最终走向腹膜纤维化,使得腹膜超滤量下降,患者无法再利用腹膜透析进行肾脏替代治疗。近年来,越来越多的研究将目光聚集在腹膜纤维化的防治上,利用涌现出的"新药"开展了一系列的细胞实验以及动物实验,在这些实验中尤以吡非尼酮对纤维化的防治效果引人注目。本文将针对近年来防治腹膜纤维化试验成果进行总结,同时对吡非尼酮的临床应用前景进行阐述。Peritoneal fibrosis（PF） is the main cause that makes the end-stage renal disease（ESRD） patients withdraw from the peritoneal dialysis treatment. As the peritoneal tissue is immersed in the peritoneal dialysis fluid continuously,the function and morphology of peritoneal membrane are altered,leading to eventual PF,decline of peritoneal ultrafiltration volume,so that peritoneal dialysis cannot be used for treatment of ESRD patients. In recent years,more and more researches have focused on the prevention and treatment of peritoneal fibrosis. ＂Novel drugs＂have been applied in cellular and animal models,among which pirfenidone is more remarkable for its antifibrotic activities. Here,this paper reviewed the progress of research on PF prevention and treatment in recent years, and the prospect of pirfenidone in clinical application was also discussed.

关 键 词：腹膜透析 腹膜纤维化 吡非尼酮 动物模型 

分 类 号：R692.5[医药卫生—泌尿科学]